Annual Cash & Cash Equivalents
$188.89 M
+$154.03 M+441.82%
December 31, 2023
Summary
- As of February 21, 2025, SYRE annual cash & cash equivalents is $188.89 million, with the most recent change of +$154.03 million (+441.82%) on December 31, 2023.
- During the last 3 years, SYRE annual cash & cash equivalents has risen by +$98.80 million (+109.66%).
- SYRE annual cash & cash equivalents is now at all-time high.
Performance
SYRE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$71.58 M
+$26.44 M+58.56%
September 30, 2024
Summary
- As of February 21, 2025, SYRE quarterly cash and cash equivalents is $71.58 million, with the most recent change of +$26.44 million (+58.56%) on September 30, 2024.
- Over the past year, SYRE quarterly cash and cash equivalents has stayed the same.
- SYRE quarterly cash and cash equivalents is now -69.59% below its all-time high of $235.36 million, reached on June 30, 2023.
Performance
SYRE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SYRE Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +441.8% | 0.0% |
| 3 y3 years | +109.7% | +83.6% |
| 5 y5 years | +741.0% | +83.6% |
SYRE Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +1147.5% | -69.6% | +389.0% |
| 5 y | 5-year | at high | +1147.5% | -69.6% | +468.4% |
| alltime | all time | at high | +7120.7% | -69.6% | +2636.2% |
Spyre Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $71.58 M(+58.6%) |
| Jun 2024 | - | $45.14 M(-80.2%) |
| Mar 2024 | - | $227.55 M(+20.5%) |
| Dec 2023 | $188.89 M(+441.8%) | $188.89 M(+108.5%) |
| Sep 2023 | - | $90.59 M(-61.5%) |
| Jun 2023 | - | $235.36 M(+567.8%) |
| Mar 2023 | - | $35.24 M(+1.1%) |
| Dec 2022 | $34.86 M(+130.2%) | - |
| Dec 2022 | - | $34.86 M(-10.6%) |
| Sep 2022 | - | $38.99 M(+4.1%) |
| Jun 2022 | - | $37.47 M(+156.0%) |
| Mar 2022 | - | $14.64 M(-3.3%) |
| Dec 2021 | $15.14 M(-83.2%) | $15.14 M(-38.6%) |
| Sep 2021 | - | $24.66 M(-29.1%) |
| Jun 2021 | - | $34.77 M(-56.7%) |
| Mar 2021 | - | $80.23 M(-10.9%) |
| Dec 2020 | $90.09 M(+368.0%) | $90.09 M(+66.2%) |
| Sep 2020 | - | $54.22 M(-17.5%) |
| Jun 2020 | - | $65.71 M(+421.8%) |
| Mar 2020 | - | $12.59 M(-34.6%) |
| Dec 2019 | $19.25 M | $19.25 M(-21.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2019 | - | $24.55 M(-3.5%) |
| Jun 2019 | - | $25.43 M(-70.3%) |
| Mar 2019 | - | $85.64 M(+281.3%) |
| Dec 2018 | $22.46 M(+75.2%) | $22.46 M(+54.6%) |
| Sep 2018 | - | $14.53 M(-29.4%) |
| Jun 2018 | - | $20.58 M(+91.3%) |
| Mar 2018 | - | $10.76 M(-16.0%) |
| Dec 2017 | $12.82 M(-73.2%) | $12.82 M(-2.6%) |
| Sep 2017 | - | $13.16 M(-51.1%) |
| Jun 2017 | - | $26.93 M(+60.3%) |
| Mar 2017 | - | $16.80 M(-64.8%) |
| Dec 2016 | $47.75 M(+63.0%) | $47.75 M(-3.6%) |
| Sep 2016 | - | $49.54 M(-29.9%) |
| Jun 2016 | - | $70.63 M(+194.1%) |
| Mar 2016 | - | $24.02 M(-18.0%) |
| Dec 2015 | $29.29 M(+1019.8%) | $29.29 M(-5.0%) |
| Sep 2015 | - | $30.84 M(-21.1%) |
| Jun 2015 | - | $39.08 M(-10.8%) |
| Mar 2015 | - | $43.79 M(+1574.0%) |
| Dec 2014 | $2.62 M(-43.1%) | $2.62 M |
| Dec 2013 | $4.60 M | - |
FAQ
- What is Spyre Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Spyre Therapeutics?
- What is Spyre Therapeutics annual cash & cash equivalents year-on-year change?
- What is Spyre Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Spyre Therapeutics?
- What is Spyre Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Spyre Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of SYRE is $188.89 M
What is the all time high annual cash & cash equivalents for Spyre Therapeutics?
Spyre Therapeutics all-time high annual cash & cash equivalents is $188.89 M
What is Spyre Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, SYRE annual cash & cash equivalents has changed by +$154.03 M (+441.82%)
What is Spyre Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SYRE is $71.58 M
What is the all time high quarterly cash and cash equivalents for Spyre Therapeutics?
Spyre Therapeutics all-time high quarterly cash and cash equivalents is $235.36 M
What is Spyre Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, SYRE quarterly cash and cash equivalents has changed by $0.00 (0.00%)